All News

Article

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Article

NSAIDs in Pregnancy (3.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Dr Gurdeep Dulay Tweet
gurdeep_dulay
Great tips for #AxSpA monitoring and 🚩 red flags for radiographic progression 🚩 ❌No need for routine imaging follow-up #RNL2023 @deodhara https://t.co/PAFtHIrqRF
Robert B Chao, MD Tweet
doctorRBC
Is AS transmission to offspring more common from the mother or father? - hard to say, some studies (including Swiss and UK studies) show mothers play a larger role - other studies show fathers do @RheumNow #RNL2023 https://t.co/Vr1qUy5Y6b
Robert B Chao, MD Tweet
doctorRBC
AxSpA is primarily a genetic disease - clusters in families, especially HLA-B27+ first degree relatives - genetic testing for asymptomatic relatives not recommended @RheumNow #RNL2023 https://t.co/vhBlNlXMHR
Eric Dein Tweet
ericdeinmd
#RNL2023 @RheumNow Atul Deodhar: Prevalence of AS is increasing! Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/qNwUg5RtaG
Eric Dein Tweet
ericdeinmd
Atul Deodhar's "3-4-5" Rule for MRI Sacroiliac Jts (SIJ) Erosion in 3+ SIJ quadrants Bone marrow edema 4+ SIJ quadrants Fat lesion in 5+ SI joint @Rheumnow #RNL2023 https://t.co/AHZUhhEmmC
Dr. Rachel Tate Tweet
uptoTate
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/2m8TmkQo0A
Robert B Chao, MD Tweet
doctorRBC
Dr. Atul Deodhar on AxSpA - 5-40% of nr-axSpA progress to r-axSpA over 2-10 years - is non-radiographic axSpA a misnomer? @RheumNow #RNL2023 https://t.co/bhwlbg6eWN
Eric Dein Tweet
ericdeinmd
Risk factors for radiographic progression: Men ♂️ Smoking 🚬 Active inflammation🔥 Blue collar workers 💪 HLA-B27+ 💉 Pre-existing syndesmophyte 🩻 Atul Deodhar at #RNL2023 @RheumNow https://t.co/9ibHTEhi9k
Eric Dein Tweet
ericdeinmd
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Robert B Chao, MD Tweet
doctorRBC
First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab biosimilar - 66% of either arm prevented radiographic progression - no difference between two arms but good news is radiographic progression is low! @RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Dr. Rachel Tate Tweet
uptoTate
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Robert B Chao, MD Tweet
doctorRBC
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi
Eric Dein Tweet
ericdeinmd
Dennis Poddubnyy #RNL2023 MRI sequences for axSpA: Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression Semi-axial- T2 STIR @RheumNow https://t.co/ySk4hU5lMY
Robert B Chao, MD Tweet
doctorRBC
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/3ZZHr0akrR
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×